Late Breaking News
LAS VEGAS, NV — Of the 30 finalists in this year’s Next Generation Pharmacist awards, 30% worked in military or public health pharmacies, the strongest representation seen in the awards program.
FT. WORTH, TX — The first treatment for facial erythema in adults caused by rosacea has been approved by the Food and Drug Administration.
SUMMIT, NJ — The approved uses of Abraxane — paclitaxel protein-bound particles for injectable suspension, albumin-bound — have been expanded by the Food and Drug Administration to treat patients with metastatic pancreatic cancer in late stages.
DEERFIELD, IL — Brintellix (vortioxetine) has been approved by the Food and Drug Administration to treat adults with major depressive disorder (MDD).
Salvaged Drugs Mean $700,000 in Annual Savings at Walter Reed
BETHESDA, MD - With increasing shortages of critical chemotherapy drugs - and the funds to buy them — VA pharmacists are constantly looking for ways to enable the medications and money to go farther so that more patients can be treated.
FALLS CHURCH, VA - After saving $22 million in Phase One, the Navy Pharmacy Financial Improvement Program has expanded from establishing target inventory levels to refining stock levels based on demand and availability - resulting in another $13.5 million in savings.
RESEARCH TRIANGLE PARK, NC - Two new therapies, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved for patients with metastatic or unresectable melanoma, according to the Food and Drug Administration.
INDIANAPOLIS, IN - For the first time, the U.S. Food and Drug Administration is allowing marketing of an HbA1c test specifically for diagnosing diabetes.
SAN FRANCISCO - The antibiotic Vibativ (telavancin) is now approved to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus.
DEERFIELD, IL - Lubiprostone, marketed as Amitiza by Sucampo Pharmaceuticals Inc. and its partner Takeda Pharmaceuticals USA Inc., has been approved by the Food and Drug Administration (FDA) as the first oral treatment for opioid-induced constipation in adults with chronic noncancer pain.
Most Popular Stories
- Many Healthcare Providers Lose VA Retention Bonuses
- Federal Medicine Organizational Meetings — Tarred with the Same Brush?
- Despite Formulary, High-Cost Diabetes Drug Use Varies Widely Across VA Facilities
- Report Says Administration Faces Hard Choices For Veterans Programs
- Physician Overcomes TBI to Return to Active-Duty Medicine
Join Our E-Mail List